Related Experiment Videos
[Mortality in treated sleep apnea syndrome]
1Service de Pneumologie, Hôpital de Hautepierre, CHU Strasbourg. ari.chaouat@chru-strasbourg.fr
Revue Neurologique
|December 4, 2003
Summary
Continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea significantly reduces mortality risk. When patients with chronic respiratory disease are excluded, CPAP-treated individuals show mortality rates comparable to the general population.
Area of Science:
- Cardiology
- Pulmonology
- Sleep Medicine
Context:
- Obstructive sleep apnea (OSA) is prevalent and linked to hypertension, stroke, coronary disease, and premature death.
- Continuous positive airway pressure (CPAP) is an established treatment for OSA, improving sleepiness and quality of life.
Purpose:
- To assess long-term mortality in patients with obstructive sleep apnea treated with nasal CPAP.
- To identify independent predictors of mortality in OSA patients receiving CPAP therapy.
Summary:
- A 11-year study followed 296 OSA patients treated with CPAP. Overall mortality was 7% at 5 years, with cardiovascular disease being the main cause of death.
- Independent mortality predictors included smoking history (>30 pack-years), age, and forced expiratory volume in 1 second (FEV1).
- Excluding 52 patients with co-existing chronic obstructive pulmonary disease (COPD), the 5-year mortality rate for the remaining 244 OSA patients was 2%, similar to the general population.
Impact:
- Nasal CPAP therapy appears to mitigate the increased risk of premature death associated with obstructive sleep apnea.
- Mortality rates in CPAP-treated OSA patients approach those of the general population, especially when comorbid chronic respiratory conditions are absent.